Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.14
(0.0%)
USD 0.14
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 56.81 Thousand AUD | 103.39% |
| 2023 | 27.93 Thousand AUD | 143.29% |
| 2022 | -64.52 Thousand AUD | 17.89% |
| 2021 | -78.58 Thousand AUD | 63.12% |
| 2020 | -213.11 Thousand AUD | -107.16% |
| 2019 | 2.97 Million AUD | 11.56% |
| 2018 | 2.66 Million AUD | 47.63% |
| 2017 | 1.8 Million AUD | 40.26% |
| 2016 | 1.28 Million AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -4494.00 AUD | 93.88% |
| 2024 Q2 | -73.39 Thousand AUD | 0.0% |
| 2024 Q1 | - AUD | 100.0% |
| 2024 Q4 | 61.3 Thousand AUD | 1464.17% |
| 2024 FY | -89.92 Thousand AUD | -421.93% |
| 2023 Q2 | -79.55 Thousand AUD | -5899.32% |
| 2023 Q4 | -46.17 Thousand AUD | -401.94% |
| 2023 Q1 | -1326.00 AUD | 99.02% |
| 2023 FY | 27.93 Thousand AUD | 143.29% |
| 2023 Q3 | 15.29 Thousand AUD | 119.22% |
| 2022 Q2 | -122.31 Thousand AUD | -861.29% |
| 2022 Q4 | -135.46 Thousand AUD | -593.25% |
| 2022 FY | -64.52 Thousand AUD | 17.89% |
| 2022 Q3 | -19.54 Thousand AUD | 84.02% |
| 2022 Q1 | -12.72 Thousand AUD | 93.14% |
| 2021 Q4 | -185.46 Thousand AUD | -371.99% |
| 2021 FY | -78.58 Thousand AUD | 63.12% |
| 2021 Q1 | - AUD | 100.0% |
| 2021 Q2 | -103.18 Thousand AUD | 0.0% |
| 2021 Q3 | -39.29 Thousand AUD | 61.92% |
| 2020 Q3 | -412.97 Thousand AUD | -200.0% |
| 2020 FY | -213.11 Thousand AUD | -107.16% |
| 2020 Q2 | 412.97 Thousand AUD | -0.0% |
| 2020 Q1 | 412.97 Thousand AUD | -72.06% |
| 2020 Q4 | -412.97 Thousand AUD | 0.0% |
| 2019 Q4 | 1.47 Million AUD | 0.0% |
| 2019 Q1 | 14.07 Thousand AUD | -98.94% |
| 2019 Q2 | 14.07 Thousand AUD | 0.0% |
| 2019 Q3 | 1.47 Million AUD | 10403.83% |
| 2019 FY | 2.97 Million AUD | 11.56% |
| 2018 Q3 | 1.33 Million AUD | 11810.84% |
| 2018 FY | 2.66 Million AUD | 47.63% |
| 2018 Q4 | 1.33 Million AUD | 0.0% |
| 2018 Q2 | 11.16 Thousand AUD | -0.01% |
| 2018 Q1 | 11.16 Thousand AUD | -98.73% |
| 2017 Q3 | 882.84 Thousand AUD | 2964.69% |
| 2017 Q2 | 28.8 Thousand AUD | -0.0% |
| 2017 Q1 | 28.8 Thousand AUD | -95.37% |
| 2017 FY | 1.8 Million AUD | 40.26% |
| 2017 Q4 | 882.84 Thousand AUD | 0.0% |
| 2016 Q1 | 23.04 Thousand AUD | 0.0% |
| 2016 Q3 | 622.24 Thousand AUD | 2599.8% |
| 2016 Q4 | 622.24 Thousand AUD | 0.0% |
| 2016 FY | 1.28 Million AUD | 0.0% |
| 2016 Q2 | 23.04 Thousand AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.621% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -1731.464% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.42% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.515% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.952% |
| Mesoblast Limited | -35.16 Million USD | 100.162% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 266.36% |
| Genus plc | 178.7 Million USD | 99.968% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 86.149% |
| Marizyme, Inc. | 457.7 Thousand USD | 87.588% |
| ContraFect Corporation | -154 Thousand USD | 136.891% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 616.473% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 213.624% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 25.988% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 13.565% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 114.661% |
| MultiCell Technologies, Inc. | 49.32 USD | -115090.592% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.859% |
| EV Biologics, Inc. | 48.9 Thousand USD | -16.18% |
| Q BioMed Inc. | -8988.00 USD | 732.087% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.799% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 468.335% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.974% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 18.84% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 145.724% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 8.701% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1247.254% |
| Arch Therapeutics, Inc. | -2439.00 USD | 2429.315% |
| IMV Inc. | -962.29 Thousand USD | 105.904% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 59.564% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 158.26% |
| GB Sciences, Inc. | -624.00 USD | 9204.487% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 166.039% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.999% |
| Halberd Corporation | -208.00 USD | 27413.462% |
| Enzolytics Inc. | 30.7 Thousand USD | -85.007% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 95.814% |
| SYBLEU INC | 11.69 Thousand USD | -385.739% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 88.224% |
| argenx SE | 1.1 Billion USD | 99.995% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.22% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 90.798% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.986% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 741.509% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.872% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 104.977% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 94.25% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.409% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 167.755% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.632% |
| ONE Bio Corp. | 20.12 Million USD | 99.718% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 580.034% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 217.723% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 67.823% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 67.823% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 111.042% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 109.016% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 295.903% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 87.376% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 117.781% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 98.767% |
| Bioxytran, Inc. | -8285.00 USD | 785.721% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 115.231% |
| Neutra Corp. | 14.33 Thousand USD | -296.317% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 169.283% |
| PureTech Health plc | -1.6 Million USD | 103.544% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 105.674% |
| IXICO plc | 3.27 Million USD | 98.263% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 108.186% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 103.172% |
| CSL Limited | 7.7 Billion USD | 99.999% |
| Cellectis S.A. | 18 Thousand USD | -215.622% |